Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
ACADEMIA
KOL Highlights Need for Further RSV Epidemiological Research in Japan
As Japan sees the arrival of the world’s first respiratory syncytial virus (RSV) vaccine, a prominent infectious disease specialist stresses the importance of conducting further epidemiological studies to discern the RSV-associated disease burdens on the country’s older populations. In January,…
To read the full story
Related Article
- OB/GYN Sees Abrysvo Becoming Part of Prenatal Care as NIP Drives Uptake
August 25, 2026
- Pfizer, ASKA to Co-Promote RSV Vaccine Abrysvo in Japan
March 9, 2026
- Pfizer’s RSV Vaccine Abrysvo Now Available in Japan
June 3, 2024
- Expert Says RSV Shots Will Have Significant Clinical Impact, Urges Public Funding and NIP Inclusion
March 8, 2024
ACADEMIA
- Japan Medical Societies Release Tavneos Discontinuation Guidance
November 6, 2026
- Tavneos Patients Shift to Other Therapies as Japan Weighs Revocation: Investigator
November 4, 2026
- Early Pregnancy DOAC Exposure Not Linked to Higher Birth Defect Risk: Study
October 30, 2026
- First iPS Heart Sheet Patient Recovering Well, Set for Discharge
October 22, 2026
- HPV Expert Backs Routine Shots for Males, Urges Broader Assessment
October 7, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…